Advanced

AJNR - American Journal of Neuroradiology

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by White, M. L. Articles by Ryken, T. C. Search for Related Content PubMed PubMed Citation Articles by White, M. L. Articles by Ryken, T. C.

American Journal of Neuroradiology 26:784-790, April 2005
© 2005 American Society of Neuroradiology

BRAIN

Can Tumor Contrast Enhancement Be Used as a Criterion for Differentiating Tumor Grades of Oligodendrogliomas?

Matthew L. White^a, Yan Zhang^a, Patricia Kirby^b and Timothy C. Ryken^c

^a Department of Radiology, University of Iowa College of Medicine, Iowa City
^b Department of Pathology, University of Iowa College of Medicine, Iowa City
^c Department of Neurosurgery, University of Iowa College of Medicine, Iowa City

Address reprint requests to Matthew L White, MD, 3959 JPP, Department of Radiology, University of Iowa College of Medicine, Iowa City, IA 52242; e-mail: matthew-white{at}uiowa.edu

BACKGROUND AND PURPOSE: The association of high-grade oligodendrogliomas with tumor contrast material enhancement on MR images has been reported. Some authors have even used contrast enhancement as a criterion for their oligodendroglioma grading system. The purpose of our study was to evaluate if tumor contrast enhancement is a specific finding for anaplastic oligodendroglioma.

METHODS: Pretreatment MR images of 24 oligodendrogliomas were reviewed retrospectively, and findings were compared with the histologic grade. The presence or absence and the pattern of tumor contrast enhancement were evaluated qualitatively. A contrast enhancement ratio (CER), a quantitative criterion, was calculated to assess the difference in degree of enhancement between the low-grade and anaplastic tumors. Tumor grade was diagnosed at pathologic examination according to the World Health Organization classification system.

RESULTS: Contrast enhancement was noted in nine (56%) of 16 low-grade tumors and in five (62%) of eight anaplastic tumors. A characteristic enhancement pattern, nodular-like enhancement, was found in eight tumors. The CERs were 2.12–40.88 (mean, 20.08) in low-grade tumors and were 3.20–62.52 (mean, 28.73) in anaplastic tumors (P > .05).

CONCLUSION: Tumor contrast enhancement was not statistically significantly different between the tumor groups. We believe that the presence or absence of tumor contrast enhancement is not a specific finding for simply discriminating low-grade from anaplastic oligodendrogliomas. Histologic confirmation is necessary even in tumors without contrast enhancement.

This article has been cited by other articles:

				M. SEIZ, P. KOHLHOF, M. A. BROCKMANN, E. NEUMAIER-PROBST, P. HERMES, A. VON DEIMLING, P. VAJKOCZY, K. SCHMIEDER, and J. TUETTENBERG First Experiences with Low-dose Anti-angiogenic Treatment in Gliomatosis Cerebri with Signs of Angiogenic Activity Anticancer Res, August 1, 2009; 29(8): 3261 - 3267. [Abstract] [Full Text] [PDF]

				N. Danchaivijitr, A. D. Waldman, D. J. Tozer, C. E. Benton, G. Brasil Caseiras, P. S. Tofts, J. H. Rees, and H. R. Jager Low-Grade Gliomas: Do Changes in rCBV Measurements at Longitudinal Perfusion-weighted MR Imaging Predict Malignant Transformation? Radiology, April 1, 2008; 247(1): 170 - 178. [Abstract] [Full Text] [PDF]

				M. V. Spampinato, J. K. Smith, L. Kwock, M. Ewend, J. D. Grimme, D. L. A. Camacho, and M. Castillo Cerebral Blood Volume Measurements and Proton MR Spectroscopy in Grading of Oligodendroglial Tumors Am. J. Roentgenol., January 1, 2007; 188(1): 204 - 212. [Abstract] [Full Text] [PDF]